All News
BSR Guideline for Psoriatic Arthritis - 2022 Update
The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients with psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic drug, typically methotrexate typically. They noted that up to 50% of people with PsA require biologic or targeted synthetic (b/ts)DMARD therapy.
Read Article
EULAR 2022 – Day 4 Report
Bags are packed, ready to go, but wait there’s more abstracts to show.
The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased.
Read Article
EULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article
EULAR 2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
Updates in Psoriatic Arthritis at EULAR 2022
At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.
Read Article
EULAR 2022 Featured Industry Abstracts
Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
Read Article
Giant Cell Arteritis Growing More Lethal
Mortality rates among patients with giant cell arteritis (GCA) in Canada's Ontario province rose by 15% from 2000 to 2018, a new study found, even as the general population saw declines in overall mortality.
Read Article
Immune Checkpoint Inhibitor Associated Arthritis
Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients.
Read Article
Bridge Prednisone Use Fails to Improve Outcomes
A one year, X-ray outcome trial has shown that the initial use of prednisone (high or low dose) in newly treated active early rheumatoid arthritis (RA) did not improve radiographic outcomes.
Read Article
RNL 2022: Rheumatoid Arthritis - Best Management
This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:
Read Article
Recommendations – Good & Bad (5.27.2022)
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
Read Article
